Related Experiment Videos
Development of beta-lactamase inhibitors
1Beecham Pharmaceuticals Research Division, Betchworth, Surrey, England.
The Journal of Reproductive Medicine
|March 1, 1990
Summary
Beta-lactamase inhibitors combat antibiotic resistance by preventing bacterial enzymes from destroying crucial drugs. Clavulanic acid and sulbactam are key examples, protecting antibiotics like amoxicillin.
Area of Science:
- Microbiology
- Pharmacology
- Biochemistry
Background:
- Bacterial resistance to beta-lactam antibiotics, linked to beta-lactamase enzyme production since 1940, poses a significant clinical challenge.
- Increasing isolation of beta-lactamase-producing bacteria necessitates strategies to overcome antibiotic inactivation of penicillins and cephalosporins.
Purpose of the Study:
- To explore the development and clinical application of beta-lactamase inhibitors as a solution to antibiotic resistance.
- To highlight the role of specific inhibitors like clavulanic acid and sulbactam in combating resistant bacterial infections.
Main Methods:
- Identification of naturally occurring beta-lactamase inhibitors through screening programs.
- Formulation of beta-lactam antibiotics with beta-lactamase inhibitors to create combination therapies.
- Clinical isolation and characterization of beta-lactamase-producing bacteria.
Main Results:
- Clavulanic acid, a Streptomyces clavuligerus metabolite, was the first clinically available beta-lactamase inhibitor.
- Clavulanic acid effectively inhibits many bacterial beta-lactamases and is formulated with amoxicillin and ticarcillin for broad-spectrum activity.
- Sulbactam and its prodrug sultamicillin are other commercially available beta-lactamase inhibitors.
Conclusions:
- Beta-lactamase inhibitors represent a successful strategy for overcoming antibiotic resistance.
- The development of inhibitors like clavulanic acid has led to effective combination therapies against resistant bacteria.